Clinical trials: Hyperhidrosis
Hyperhidrosis, Muscle Spasticity
Safety and Efficacy of BOTOX® (Botulinum Toxin Type A) in Korea
This post marketing surveillance study in Korea will evaluate the safety and efficacy of BOTOX (botulinum toxin Type A) in patients who receive treatment according to standard of care for primary axillary hyperhidrosis, focal…
- Conditions
- Hyperhidrosis, Muscle Spasticity, Glabellar Lines
- Trial name
- NCT02043145
- Testing
- botulinum toxin Type A
- Where
- South Korea
- Volunteers
- 727 people
- Sponsor
- Allergan
Axillary Hyperhidrosis
Safety and Efficacy Study of Sofpironium Bromide in Subjects With Axillary Hyperhidrosis (BBI-4000-CL-302)
Hyperhidrosis is a disorder of abnormal excessive sweating. Primary hyperhidrosis (armpits, hands, and feet) affects approximately 4.8% of the US population and is believed to be caused by an overactive cholinergic response of…
- Trial name
- CARDIGANII (NCT03948646)
- Testing
- Sofpironium Bromide, 15%, Vehicle
- Where
- 42 sites in United States
- Volunteers
- 351 people
- Sponsor
- Botanix Pharmaceuticals
Hyperhidrosis
Clinical Trial To Evaluate ANT-1207 In Participants With Primary Axillary Hyperhidrosis
The purpose of this study is to establish the therapeutic range of ANT-1207 in the treatment of primary axillary hyperhidrosis.
- Trial name
- NCT02479139
- Testing
- Vehicle, ANT-1207
- Where
- 19 sites in United States
- Volunteers
- 145 people
- Sponsor
- Allergan
Hyperhidrosis
Evaluation of 1440nm Laser vs. Botulinum Toxin or miraDry® Microwave For Treatment of Axillary Hyperhidrosis
The Purpose of the study is to evaluate the 1440nm Laser Assisted Selective Photothermolysis vs. Botulinum Toxin or miraDry® Microwave Thermolysis For Treatment of Axillary Hyperhidrosis.
- Trial name
- NCT01811004
- Testing
- miraDry, Nd:YAG Laser, Botox®
- Where
- United States
- Volunteers
- 17 people
- Sponsor
- Cynosure, Inc.
Hyperhidrosis
A Dose-Ranging Study of the Effect of Glycopyrrolate in Subjects With Axillary Hyperhidrosis
The purpose of this study is to evaluate the safety and efficacy of glycopyrrolate compared to vehicle for the treatment of axillary hyperhidrosis.
- Trial name
- NCT02016885
- Testing
- glycopyrrolate, 1.0%, glycopyrrolate, 2.0%, glycopyrrolate, 3.0%
- Where
- 21 sites in United States
- Volunteers
- 198 people
- Sponsor
- Journey Medical Corporation
Primary Focal Hyperhidrosis of the Hands
BTX-A Treatment for Palmar Hyperhidrosis
Primary focal hyperhidrosis (excessive sweating) is a debilitating condition affecting approximately 3% of the population in the United States.
- Trial name
- NCT01262339
- Testing
- BTX-A
- Where
- United States
- Volunteers
- 2 people
- Sponsor
- University of Wisconsin, Madison
Primary Focal Hyperhidrosis, Axilla
Efficacy and Safety of the DTS-G2 System in Patients With Axillary Hyperhidrosis
This is a prospective, multi-center, parallel, randomized, blinded study. The study has two groups, where in one study group the subjects receive treatment for axillary hyperhidrosis (excessive underarm sweating) with the DTS-G2…
- Trial name
- DRI-UP (NCT00931359)
- Testing
- DTS-G2 System
- Where
- 7 sites in United States
- Volunteers
- 120 people
- Sponsor
- Miramar Labs
Hyperhidrosis
Evaluation of 1440nm Laser Assisted Selective Photothermolysis for Treatment of Axillary Hyperhidrosis
The purpose of this study is to evaluate the safety and efficacy of the Nd:YAG 1440 nm wavelength laser for the treatment of primary hyperhidrosis of the axilla.
- Trial name
- NCT02100072
- Testing
- Nd:YAG 1440 nm laser
- Where
- United States
- Volunteers
- 5 people
- Sponsor
- Cynosure, Inc.
Hyperhidrosis
GSK1358820 (Botulinum Toxin A) PhIII DB & OL Study in Patients With Axillary Hyperhidrosis
The primary objective of this study is to demonstrate superiority of single treatment of GSK1358820 (hereinafter, referred to as BOTOX®) over placebo in terms of the efficacy of treatment with BOTOX® 50 U in each axilla (100 U in…
- Trial name
- NCT01128738
- Testing
- GSK1358820
- Where
- 14 sites in Japan
- Volunteers
- 152 people
- Sponsor
- GlaxoSmithKline
Axillary Hyperhidrosis
Safety and Efficacy Study of Sofpironium Bromide in Subjects With Axillary Hyperhidrosis (BBI-4000-CL-301)
Hyperhidrosis is a disorder of abnormal excessive sweating. Primary hyperhidrosis (armpits, hands, and feet) affects approximately 4.8% of the US population and is believed to be caused by an overactive cholinergic response of…
- Trial name
- CardiganI (NCT03836287)
- Testing
- Sofpironium Bromide Gel, 15%, Vehicle
- Where
- 39 sites in United States
- Volunteers
- 350 people
- Sponsor
- Botanix Pharmaceuticals
Palmar Hyperhidrosis
A Study of Glycopyrronium Cloth, 2.4% in Patients With Palmar Hyperhidrosis
The objective of this study is to assess the efficacy and safety of glycopyrronium cloth, 2.4% when used to treat palmar hyperhidrosis.
- Trial name
- NCT03880266
- Testing
- Glycopyrronium cloth, 2.4%, Vehicle
- Where
- 7 sites in United States
- Volunteers
- 72 people
- Sponsor
- Journey Medical Corporation
Amputation, Hyperhidrosis
Qbrexza Cloths for Hyperhidrosis of Amputation Sites
This is a Prospective, Double Blinded, Placebo Controlled, Randomized, Cross-over trial using Qbrexza Cloths to treat hyperhidrosis of amputation sites.
- Trial name
- NCT04924036
- Testing
- glycopyrronium cloths
- Where
- United States
- Volunteers
- 13 people
- Sponsor
- University of Utah
Primary Axillary Hyperhidrosis
Evaluation of N-SWEAT Patch for Treatment of Primary Axillary Hyperhidrosis or Excessive Axillary Sweating
The Sahara Study is a study to evaluate the safety and effectiveness of the N-SWEAT Patch for use in subjects with excessive axillary sweating, or primary focal axillary hyperhidrosis.
- Trial name
- NCT04599907
- Testing
- Roll-In Cohort: Single Application of N-SWEAT Patch, Randomized Cohort: Single Application of N-SWEAT Patch
- Where
- 9 sites in United States
- Volunteers
- 120 people
- Sponsor
- Candesant Biomedical, Inc.
Hyperhidrosis
Long-term Safety Study of Glycopyrronium in Subjects With Primary Axillary Hyperhidrosis
This is an open-label, long-term safety study of glycopyrronium topical wipes, enrolling up to 660 subjects with primary axillary hyperhidrosis who participated in either the DRM04-HH04 or DRM04-HH05 studies.
- Trial name
- NCT02553798
- Testing
- Glycopyrronium Topical Wipes
- Where
- 48 sites in United States, Germany
- Volunteers
- 564 people
- Sponsor
- Journey Medical Corporation
Axillary Hyperhidrosis
Botox and Suction-Curettage for Treatment of Excessive Underarm Sweating (Axillary Hyperhidrosis)
The purpose of this study is to compare the effectiveness of two methods in the treatment of excessive underarm sweating (axillary hyperhidrosis): suction-curettage and Botox injections.
- Trial name
- NCT01274611
- Testing
- Botulinum Toxin Type A, Suction-Curettage
- Where
- United States
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- Northwestern University
HYPERHIDROSIS
Investigation of Hyperhidrosis Treatment Using the Nd: YAG 1440nm Wavelength Laser
The purpose of this study is to evaluate the safety and efficacy of the Nd:YAG 1440 nm wavelength laser for the treatment of primary hyperhidrosis of the axilla.
- Trial name
- NCT01810991
- Testing
- Nd:YAG Laser
- Where
- United States
- Volunteers
- 19 people
- Sponsor
- Cynosure, Inc.
Hyperhidrosis
A Safety and Efficacy Study of BBI-4000 in Subjects With Axillary Hyperhidrosis
To assess the safety and efficacy of 3 doses of BBI-4000 and vehicle (4 treatment arms), when applied once a day for 4 weeks, for the treatment of axillary hyperhidrosis.
- Trial name
- NCT02336503
- Testing
- BBI-4000 Gel, 5%, BBI-4000 Gel, 10%, BBI-4000 Gel, 15%
- Where
- 12 sites in United States
- Volunteers
- 189 people
- Sponsor
- Botanix Pharmaceuticals
Primary Axillary Hyperhidrosis
A Safety Study of BBI-4000 Gel in Patients With Axillary Hyperhidrosis
Hyperhidrosis is a disorder of abnormal excessive sweating. Primary hyperhidrosis (armpits, hands, and feet) affects approximately 4.8% of the US population and is believed to be caused by an overactive cholinergic response of…
- Trial name
- NCT03627468
- Testing
- Sofpironium Bromide Gel, 5%, Sofpironium Bromide Gel, 15%
- Where
- 12 sites in United States
- Volunteers
- 300 people
- Sponsor
- Botanix Pharmaceuticals
Hyperhidrosis
A Safety, Tolerability and Preliminary Efficacy Study of BBI-4000 Gel in Subjects With Palmar Hyperhidrosis
To assess the safety and local tolerability of BBI-4000 15% gel compared with vehicle (placebo) when applied topically once daily in subjects with palmar hyperhidrosis.
- Trial name
- NCT02682238
- Testing
- BBI-4000, 15%, Vehicle gel
- Where
- 5 sites in United States
- Volunteers
- 50 people
- Sponsor
- Botanix Pharmaceuticals
Hyperhidrosis
A Confirmatory Safety and Efficacy Study of BBI-4000 in Subjects With Axillary Hyperhidrosis
This study is being conducted to assess the safety and efficacy of 3 concentrations of BBI-4000 and vehicle (4 treatment arms), applied for the treatment of axillary hyperhidrosis.
- Trial name
- NCT03024255
- Testing
- BBI-4000 gel, 5%, BBI-4000 gel, 10%, BBI-4000 gel, 15%
- Volunteers
- 227 people
- Sponsor
- Botanix Pharmaceuticals